Cochlear Limited
COH.AXHealthcareASXMedical Devices
Scan Results
Daily timeframeCochlear Limited provides implantable hearing solutions for children and adults worldwide. At a $6.20B market cap, Cochlear Limited ranks as a mid-cap company within healthcare. The company offers cochlear implant systems, sound processor upgrades, bone conduction systems, and other products.
Market Cap
$6.20B
Beta
0.24
P/E (TTM)
17.99
P/E (Fwd)
18.24
EPS (TTM)
$5.27
EPS (Fwd)
$5.20
ROE
18.1%
ROA
11.3%
Cash
$187.1M
Total Debt
$242.2M
Free CF
$104.1M
52W Change
-64.1%
Annual Financials
Cash vs Debt
The company holds $187.1M in cash, though total debt stands at $242.2M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $104.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 18.1%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 11.3% further supports the picture of efficient asset utilization. Revenue has grown from $1.65B (2022) to $2.34B (2025), reflecting a 42% increase over the period.
With a beta below 0.7, Cochlear Limited typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing COH.AX.